Towards personalized medicine with a three-dimensional micro-scale perfusion-based two-chamber tissue model system

Biomaterials

Volumn 33, Issue 17, 2012, Pages 4353-4361

  Ma, Liang ^a,b   Barker, Jeremy ^b   Zhou, Changchun ^a   Li, Wei ^a,b   Zhang, Jing ^c   Lin, Biaoyang ^b,c   Foltz, Gregory ^c   Küblbeck, Jenni ^d   Honkakoski, Paavo ^d  

^a The University of Texas at Austin   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c SWEDISH MEDICAL CENTER   (United States)

^d UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

3D cell culture; Glioblastoma; Liver CYP metabolism; Metabolism dependent toxicity; Micro scale tissue model system; Two chamber system

Indexed keywords

3-D CELL CULTURE; ANTICANCER DRUG; BRAIN CANCER; CYTOCHROME P450; EXPRESSION LEVELS; GLIOBLASTOMA MULTIFORME; GLIOBLASTOMAS; IFOSFAMIDE; IN-VITRO; LIVER CELLS; METABOLIC EFFECTS; MICRO-SCALES; MODEL SYSTEM; PERSONALIZED MEDICINES; POLYLACTIC ACIDS; SEPARATE CHAMBER; SOLVENT FREE; TEMOZOLOMIDE; TISSUE ENGINEERING SCAFFOLD; TISSUE MODELS; TWO-CHAMBER SYSTEM;

CELL CULTURE; CELLS; CYTOTOXICITY; DRUG PRODUCTS; LACTIC ACID; METABOLISM; MONOLAYERS; PHYSIOLOGY; SCAFFOLDS (BIOLOGY); TISSUE; TOXICITY;

THREE DIMENSIONAL;

CYTOCHROME P450; CYTOCHROME P450 3A4; IFOSFAMIDE; POLYLACTIC ACID; TEMOZOLOMIDE;

ANIMAL CELL; ARTICLE; CANCER CELL; CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG METABOLISM; EXPERIMENTAL MODEL; GLIOBLASTOMA; IN VITRO STUDY; LIVER METABOLISM; MOUSE; NONHUMAN; PERFUSION; PERSONALIZED MEDICINE; PRIORITY JOURNAL; THREE DIMENSIONAL IMAGING; THREE DIMENSIONAL MICRO SCALE PERFUSION BASED TWO CHAMBER TISSUE MODEL SYSTEM;

CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELL SURVIVAL; CYTOCHROME P-450 CYP3A; DACARBAZINE; DIFFUSION CHAMBERS, CULTURE; GLIOBLASTOMA; HUMANS; IFOSFAMIDE; INDIVIDUALIZED MEDICINE; LIVER; MICROSCOPY, ELECTRON, SCANNING; PERFUSION; POLYESTERS; POROSITY; TISSUE ENGINEERING; TISSUE SCAFFOLDS;

EID: 84862811634     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.02.054     Document Type: Article

References (68)

1. Evans W.E., Relling M.V. Moving towards individualized medicine with pharmacogenomics. Nature 2004, 429:464-468.
2. Ekins S., Ring B.J., Grace J., McRobie-Belle D.J., Wrighton S.A. Present and future in vitro approaches for drug metabolism. J Pharmacol Toxicol Methods 2000, 44:313-324.
3. Martinez-Jimenez C.P., Jover R., Donato M.T., Castell J.V., Gomez-Lechon M.J. Transcriptional regulation and expression of CYP3A4 in hepatocytes. Curr Drug Metab 2007, 8:185-194.
4. Brouwer K.L., Thurman R.G. Isolated perfused liver. Pharm Biotechnol 1996, 8:161-192.
5. Wolkoff A.W., Johansen K.L., Goeser T. The isolated perfused rat liver: preparation and application. Anal Biochem 1987, 167:1-14.
6. Lerche-Langrand C., Toutain H.J. Precision-cut liver slices: characteristics and use for in vitro pharmaco-toxicology. Toxicology 2000, 153:221-253.
7. Neupert G., Glockner R., Muller D. Immunohistochemical localization of cytochrome P450 1A1 in precision-cut rat liver slices after in vitro exposure to beta-naphthoflavone. Exp Toxicol Pathol 1998, 50:514-518.
8. Muller D., Glockner R., Rost M., Steinmetzer P. Monooxygenation, cytochrome P450-mRNA expression and other functions in precision-cut rat liver slices. Exp Toxicol Pathol 1998, 50:507-513.
9. Glockner R., Steinmetzer P., Drobner C., Muller D. Application of cryopreserved precision-cut liver slices in pharmacotoxicology-principles, literature data and own investigations with special reference to CYP1A1-mRNA induction. Exp Toxicol Pathol 1998, 50:440-449.
10. Berry M.N., Grivell A.R., Grivell M.B., Phillips J.W. Isolated hepatocytes-past, present and future. Cell Biol Toxicol 1997, 13:223-233.
11. Vore M., Liu Y., Ganguly T.C. Isolated hepatocytes. Pharm Biotechnol 1996, 8:115-120.
12. Liu L., LeCluyse E.L., Liu J., Klaassen C.D. Sulfotransferase gene expression in primary cultures of rat hepatocytes. Biochem Pharmacol 1996, 52:1621-1630.
13. LeCluyse E.L., Bullock P.L., Parkinson A., Hochman J.H. Cultured rat hepatocytes. Pharm Biotechnol 1996, 8:121-159.
14. Gebhardt R., Hengstler J.G., Muller D., Glockner R., Buenning P., Laube B., et al. New hepatocyte in vitro systems for drug metabolism: metabolic capacity and recommendations for application in basic research and drug development, standard operation procedures. Drug Metab Rev 2003, 35:145-213.
15. Houston J.B., Carlile D.J. Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices. Drug Metab Rev 1997, 29:891-922.
16. Rodrigues A.D., Wong S.L. Application of human liver microsomes in metabolism-based drug-drug interactions: in vitro-in vivo correlations and the Abbott Laboratories experience. Adv Pharmacol 1997, 43:65-101.
17. Dixit V., Elcin Y.M. Liver tissue engineering: successes & limitations. Adv Exp Med Biol 2003, 534:57-67.
18. Powers M.J., Janigian D.M., Wack K.E., Baker C.S., Beer Stolz D., Griffith L.G. Functional behavior of primary rat liver cells in a three-dimensional perfused microarray bioreactor. Tissue Eng 2002, 8:499-513.
19. Griffith L.G., Naughton G. Tissue engineering-current challenges and expanding opportunities. Science 2002, 295:1009-1014.
20. Domansky K., Inman W., Serdy J., Dash A., Lim M.H., Griffith L.G. Perfused multiwell plate for 3D liver tissue engineering. Lab Chip 2010, 10:51-58.
21. Domansky K., Inman W., Serdy J., Griffith L. Perfused microreactors for liver tissue engineering. Conf Proc IEEE Eng Med Biol Soc 2005, 7:7490-7492.
22. Zhang S., Tong W., Zheng B., Susanto T.A., Xia L., Zhang C., et al. A robust high-throughput sandwich cell-based drug screening platform. Biomaterials 2011, 32:1229-1241.
23. Chang R., Nam Y., Sun W. Direct cell writing of 3D microorgan for in vitro pharmacokinetic model. Tissue Eng Pt C-Meth 2008, 14:157-166.
24. Chang R., Emami K., Wu H., Sun W. Biofabrication of a three-dimensional liver micro-organ as an in vitro drug metabolism model. Biofabrication 2010, 2:045004.
25. Park T.H., Shuler M.L. Integration of cell culture and microfabrication technology. Biotechnol Prog 2003, 19:243-253.
26. Chung L.W.K. Prostate carcinoma bone-stroma interaction and its biologic and therapeutic implications. Cancer 2003, 97:772-778.
27. Huang S., Van Arsdall M., Tedjarati S., McCarty M., Wu W., Langley R., et al. Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. J Natl Cancer Inst 2002, 94:1134-1142.
28. Schmeichel K.L., Bissell M.J. Modeling tissue-specific signaling and organ function in three dimensions. J Cell Sci 2003, 116:2377-2388.
29. Dhiman H.K., Ray A.R., Panda A.K. Three-dimensional chitosan scaffold-based MCF-7 cell culture for the determination of the cytotoxicity of tamoxifen. Biomaterials 2005, 26:979-986.
30. Friedrich M.J. Studying cancer in 3 dimensions: 3-D models foster new insights into tumorigenesis. JAMA 2003, 290:1977-1979.
31. Liu H., Roy K. Biomimetic three-dimensional cultures significantly increase hematopoietic differentiation efficacy of embryonic stem cells. Tissue Eng 2005, 11:319-330.
32. Bettinger C.J., Weinberg E.J., Kulig K.M., Vacanti J.P., Wang Y., Borenstein J.T., et al. Three-dimensional microfluidic tissue-engineering scaffolds using a flexible biodegradable polymer. Adv Mater 2006, 18:165-169.
33. Sung J.H., Kam C., Shuler M.L. A microfluidic device for a pharmacokinetic-pharmacodynamic (PK-PD) model on a chip. Lab Chip 2010, 10:446-455.
34. Sung J.H., Shuler M.L. A micro cell culture analog (microCCA) with 3-D hydrogel culture of multiple cell lines to assess metabolism-dependent cytotoxicity of anti-cancer drugs. Lab Chip 2009, 9:1385-1394.
35. Karande T.S., Ong J.L., Agrawal C.M. Diffusion in musculoskeletal tissue engineering scaffolds: design issues related to porosity, permeability, architecture, and nutrient mixing. Ann Biomed Eng 2004, 32:1728-1743.
36. Raucy J.L. Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products. Drug Metab Dispos 2003, 31:533-539.
37. Croom E.L., Stevens J.C., Hines R.N., Wallace A.D., Hodgson E. Human hepatic CYP2B6 developmental expression: the impact of age and genotype. Biochem Pharmacol 2009, 78:184-190.
38. Wolbold R., Klein K., Burk O., Nussler A.K., Neuhaus P., Eichelbaum M., et al. Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 2003, 38:978-988.
39. Kublbeck J., Reinisalo M., Mustonen R., Honkakoski P. Up-regulation of CYP expression in hepatoma cells stably transfected by chimeric nuclear receptors. Eur J Pharm Sci 2010, 40:263-272.
40. Tsang L.L., Quarterman C.P., Gescher A., Slack J.A. Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl-(triazen-1-yl)imidazole-4-carboxamide. Cancer Chemother Pharmacol 1991, 27:342-346.
41. Wang X., Li W., Kumar V. A method for solvent-free fabrication of porous polymer using solid-state foaming and ultrasound for tissue engineering applications. Biomaterials 2006, 27:1924-1929.
42. Wang X., Li W., Kumar V. Creating open-celled solid-state foams using ultrasound. J Cell Plastics 2009, 45:353-369.
43. Lu H., Koo L.Y., Wang W.M., Lauffenburger D.A., Griffith L.G., Jensen K.F. Microfluidic shear devices for quantitative analysis of cell adhesion. Anal Chem 2004, 76:5257-5264.
44. Albuquerque M.L., Waters C.M., Savla U., Schnaper H.W., Flozak A.S. Shear stress enhances human endothelial cell wound closure in vitro. Am J Physiol Heart Circ Physiol 2000, 279:H293-H302.
45. Kalyanaraman B., Supp D.M., Boyce S.T. Medium flow rate regulates viability and barrier function of engineered skin substitutes in perfusion culture. Tissue Eng Part A 2008, 14:583-593.
46. Toh Y.C., Zhang C., Zhang J., Khong Y.M., Chang S., Samper V.D., et al. A novel 3D mammalian cell perfusion-culture system in microfluidic channels. Lab Chip 2007, 7:302-309.
47. Abbott A. Cell culture: biology's new dimension. Nature 2003, 424:870-872.
48. Liscovitch M., Lavie Y. Cancer multidrug resistance: a review of recent drug discovery research. IDrugs 2002, 5:349-355.
49. Kim J.B. Three-dimensional tissue culture models in cancer biology. Semin Cancer Biol 2005, 15:365-377.
50. Sutherland R.M. Cell and environment interactions in tumor microregions: the multicell spheroid model. Science 1988, 240:177-184.
51. dit Faute M.A., Laurent L., Ploton D., Poupon M.F., Jardillier J.C., Bobichon H. Distinctive alterations of invasiveness, drug resistance and cell-cell organization in 3D-cultures of MCF-7, a human breast cancer cell line, and its multidrug resistant variant. Clin Exp Metastasis 2002, 19:161-168.
52. Jun H.T., Sun J., Rex K., Radinsky R., Kendall R., Coxon A., et al. AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts. Clin Cancer Res 2007, 13:6735-6742.
53. Roos W.P., Batista L.F., Naumann S.C., Wick W., Weller M., Menck C.F., et al. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene 2007, 26:186-197.
54. Baker S.D., Wirth M., Statkevich P., Reidenberg P., Alton K., Sartorius S.E., et al. Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. Clin Cancer Res 1999, 5:309-317.
55. Walker D., Flinois J.P., Monkman S.C., Beloc C., Boddy A.V., Cholerton S., et al. Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide. Biochem Pharmacol 1994, 47:1157-1163.
56. Furlanut M., Franceschi L. Pharmacology of ifosfamide. Oncology 2003, 65(Suppl. 2):2-6.
57. Purnapatre K., Khattar S.K., Saini K.S. Cytochrome P450s in the development of target-based anticancer drugs. Cancer Lett 2008, 259:1-15.
58. Nebert D.W., Russell D.W. Clinical importance of the cytochromes P450. The Lancet 2002, 360:1155-1162.
59. Sailon A.M., Allori A.C., Davidson E.H., Reformat D.D., Allen R.J., Warren S.M. A novel flow-perfusion bioreactor supports 3D dynamic cell culture. J Biomed Biotechnol 2009, 873816.
60. Provin C., Takano K., Sakai Y., Fujii T., Shirakashi R. A method for the design of 3D scaffolds for high-density cell attachment and determination of optimum perfusion culture conditions. J Biomech 2008, 41:1436-1449.
61. Smitskamp-Wilms E., Pinedo H.M., Veerman G., Ruiz van Haperen V.W., Peters G.J. Postconfluent multilayered cell line cultures for selective screening of gemcitabine. Eur J Cancer 1998, 34:921-926.
62. Yin J., Meng Q., Zhang G., Sun Y. Differential methotrexate hepatotoxicity on rat hepatocytes in 2-D monolayer culture and 3-D gel entrapment culture. Chem Biol Interact 2009, 180:368-375.
63. Ma L., Zhou C., Lin B., Li W. A porous 3D cell culture micro device for cell migration study. Biomed Microdevices 2010, 12:753-760.
64. Gilbert D.L., Okano T., Miyata T., Kim S.W. Macromolecular diffusion through collagen membranes. Int J Pharm 1988, 47:79-88.
65. Amsden B. Solute diffusion within hydrogels. Mechanisms and models. Macromolecules 1998, 31:8382-8395.
66. Saltzman W.M., Langer R. Transport rates of proteins in porous materials with known microgeometry. Biophys J 1989, 55:163-171.
67. Falk B., Garramone S., Shivkumar S. Diffusion coefficient of paracetamol in a chitosan hydrogel. Mater Lett 2004, 58:3261-3265.
68. Matyka M., Khalili A., Koza Z. Tortuosity-porosity relation in porous media flow. Phys Rev E 2008, 78. 026306:p. 1-8.